Antibody-based malaria prevention in an intense perennial transmission setting
- 23 April 2026
- journal article
- Published by Elsevier in The Lancet
- Vol. 407 (10539) , 1575-1577
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Value profile for Malaria vaccines and monoclonal antibodiesVaccine, 2025
- Malaria vaccines: a new era of prevention and controlNature Reviews Microbiology, 2024
- Vaccines and monoclonal antibodies: new tools for malaria controlClinical Microbiology Reviews, 2024
- The impact of Plasmodium-driven immunoregulatory networks on immunity to malariaNature Reviews Immunology, 2024
- The emergence of artemisinin partial resistance in Africa: how do we respond?The Lancet Infectious Diseases, 2024
- Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliNew England Journal of Medicine, 2022
- Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaNew England Journal of Medicine, 2022
- Evidence of Artemisinin-Resistant Malaria in AfricaNew England Journal of Medicine, 2021
- A Monoclonal Antibody for Malaria PreventionNew England Journal of Medicine, 2021
- A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasiteNature Medicine, 2018